Senti Biosciences Holdings (SNTI) Other Operating Expenses (2021 - 2024)
Senti Biosciences Holdings (SNTI) posted quarterly Other Operating Expenses of -$398000.0 for Q3 2024, down 238.68% year-over-year from $287000.0 in Q4 2023, and down 124.4% quarter-over-quarter from $1.6 million in Q2 2024.
Senti Biosciences Holdings (SNTI) Other Operating Expenses (2021 - 2024) Analysis & Trends
Senti Biosciences Holdings' Other Operating Expenses history runs 3 years deep, the most recent figure standing at -$398000.0 for Q3 2024.
- In Q3 2024, Other Operating Expenses fell 238.68% year-over-year to -$398000.0; the TTM figure through Jun 2025 stood at -$398000.0 (down 117.41% YoY), while the FY2024 annual figure was -$17.2 million, down 2853.99% from the prior year.
- Other Operating Expenses for Q3 2024 stood at -$398000.0, down from $1.6 million in the prior quarter.
- The five-year high for Other Operating Expenses was $1.6 million in Q2 2024, with the low at -$398000.0 in Q3 2024.
- The 3-year median for Other Operating Expenses is $158000.0 (2023), against an average of $314863.0.
- Peak annual rise in Other Operating Expenses reached 238.68% in 2024, while the deepest fall reached 238.68% in 2024.
- Senti Biosciences Holdings' Other Operating Expenses stood at $1178.0 in 2021, then surged by 28677.59% to $339000.0 in 2023, then tumbled by 217.4% to -$398000.0 in 2024.
- Business Quant data shows SNTI's Other Operating Expenses at -$398000.0 in Q3 2024, $1.6 million in Q2 2024, and $29000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Senti Biosciences Holdings | 12.06 Mn | 12.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -398,000.00 |
| Jun 30, 2024 | 1.63 Mn |
| Mar 31, 2024 | 29,000.00 |
| Dec 31, 2023 | 339,000.00 |
| Sep 30, 2023 | 287,000.00 |
| Mar 31, 2021 | 1,178.00 |